The use of targeted viral vectors to localize gene transfer to specific cell types holds many advantages over conventional, non-targeted vectors currently used in gene therapy. The resulting improvements in gene localization from targeted adenovirus vectors are likely to reduce immunogenicity and toxicity, increase safety, and enable the systemic administration of these vectors for multiple indications including cancer, cardiovascular disease, and inflammatory disease. Recent advances in the biological understanding of adenovirus structure and adenovirus receptor interactions have fueled the rapid development of targeted adenovirus vectors. Two basic requirements are necessary to create a targeted adenovirus vector: interaction of adenovirus with its native receptors must be removed and novel, tissue-specific ligands must be added to the virus. Two general approaches have been used to achieve these basic requirements. In the 'two-component' approach, a bispecific molecule is complexed with the adenovirus. The bispecific component simulKeywords: adenovirus; targeting; gene therapy; receptor; vector
The promise of targeted adenovirus
Over the last 3 years, there has been a dramatic increase in research on adenovirus targeting. In 1997, at the first Cold Spring Harbor meeting on vector targeting strategies for therapeutic gene delivery organized by Wayne Marasco and David Curiel, there were seven abstracts from six different groups relating to adenovirus targeting. Only 2 years later, at the second meeting, the number of abstracts and groups had approximately tripled to 19 abstracts from 15 different groups. One might ask why interest and research in the area has blossomed so considerably. There are many possible answers to this question. The simple answer is that the increase reflects a recognition of the success of the technology and a confidence in its ability to impact gene therapy significantly.
Adenovirus targeting is now advancing beyond the pure research stage. Currently, there are at least seven gene therapy companies with active programs in adenovirus targeting. This fact demonstrates that companies recognize the potential of this technology to overcome some of the current limitations of adenovirus vectors and gene therapy vectors in general. Most importantly, this investment reflects a growing enthusiasm and belief that this technology will be critical to obtaining efficacious Correspondence: TJ Wickham taneously blocks native receptor binding and redirects virus binding to a tissue-specific receptor. In the 'one-component' approach the adenovirus is genetically modified to ablate native receptor interactions and a novel ligand is genetically incorporated into one of the adenovirus coat proteins. Twocomponent systems offer great flexibility in rapidly validating the feasibility of targeting via a particular receptor. Onecomponent systems offer the best advantages in producing a manufacturable therapeutic and in more completely ablating all native adenovirus receptor interactions. The coming challenges for targeted adenovirus vectors will be the demonstration that the technology performs in vivo. Ultimately, or in parallel, 'receptor-targeting' technology can be combined with improved adenovirus backbones and with 'transcriptional targeting' approaches to create adenovirus which deliver genes selectively, safely, and with little immune response. Gene Therapy (2000) 7, 110-114.
gene therapy products to treat disease in the future. With this idea in mind, the field is now advancing well beyond the stage of showing the 'standard' in vitro data. Current research is now focused on demonstrating that the technology works in vivo, achieving a more detailed understanding of the critical molecular and cellular mechanisms involved in targeting, as well as developing vector systems that can be efficiently produced and taken through clinical trials. As these challenges are met, it is quite possible that the use of targeted vectors in gene therapy will become the norm rather than the exception.
To some, it is probably inherently obvious why targeted adenovirus vectors would greatly advance gene therapy. Targeted vectors should selectively localize gene expression to the tissue of interest. But what does this really mean and how does it potentially impact how gene therapy is done? Targeted adenovirus offers to impact gene therapy significantly in at least three major ways. First, targeted adenovirus vectors are likely to be safer. Even with improved purification methods, which have probably eliminated the majority of the inflammatory and toxic reactions that have been observed with adenovirus early on, it is clear that, in some tissues and at high doses, even very pure preparations of adenovirus can result in some adverse inflammatory and hematological events. While some responses can be attributed to the backbone, it is becoming increasingly clear that at least part of the response can be attributed to the adenovirus particle itself. The receptors for adenovirus are broadly expressed. They are expressed on blood cells, in most major organs, and on many immune effector cells. Adenovirus interaction with receptors on these cells could lead to toxic responses via the induction of multiple signaling cascades. By knocking out these interactions using a targeted vector, it is possible that adverse reactions to adenovirus could be significantly reduced or eliminated.
A second way that targeted adenovirus could positively impact gene therapy is through reducing both humoral and CTL-mediated immune response to the vector. The signaling events triggered through adenovirus interaction with its native receptors may enhance or initiate the immune response. For example, adenovirus binding to cells has been documented to stimulate cytokine production. By knocking out the native receptor interactions, the induction of cytokine production and potentiation of an immune response could be avoided. Immune response to adenovirus vectors could also be reduced through preventing the uptake of the vector into specialized antigen presenting cells. These cells are known to express adenovirus receptors. By ablating the interaction of adenovirus with these receptors and thus reducing uptake into these cells, both the cytotoxic T lymphocyte response as well as the humoral response to adenovirus vectors could be reduced.
The third and potentially most exciting way that targeting adenovirus could impact gene therapy is by enabling systemic administration of adenovirus vectors. Through systemic administration, targeted adenovirus vectors have the potential to transform how gene therapy is done. For example, many gene therapy protocols for the treatment of cancer have relied on intratumoral injections to deliver genes to tumors. While some success has been achieved by this approach, it presents some major disadvantages that targeted gene transfer could potentially overcome. First, for many metastatic cancers the exact locations of the metastases are often unknown. Therefore, only those tumors that are accessible and whose locations are known can be treated by this approach. Second, even if one knows where all the tumors are, gene transfer via intratumoral injection can be inefficient in transducing a majority of cells within the tumor. The vector often does not diffuse throughout the tumor but tends to localize along the needle track. Backflow of vector out of the needle track into healthy tissue or into the systemic circulation is an additional difficulty, particularly if the transgene is toxic. A final problem is that if the locations of the tumors are known and if good diffusion of vector throughout the tumor is achieved, recent evidence now suggests that many primary tumor cells appear to express very little of the primary receptor used by adenovirus to infect cells. Therefore, the efficiency of gene transfer into such tumors is likely to be reduced.
Systemic administration of vector has the potential to overcome the above deficiencies of traditional gene therapies now in use. For example, targeting adenovirus to a highly expressed receptor within a tumor overcomes the problem of efficiency of entry into the cells. By approaching the tumor from the circulation, there may be a better chance of reaching more cells within the tumor. Finally, difficult to access or undetected metastases which are vascularized are also accessible to the virus within the circulation.
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Appreciating the biology
Major advances in understanding the cellular and molecular virology of adenovirus have greatly fueled the progress that has been made in targeting adenovirus. Receptor-mediated entry of Ad into cells has been found to depend on not one, but two of its coat proteins, fiber and penton base. The fiber mediates primary attachment to the cell via the Coxsackie-adenovirus receptor (CAR) protein.
1,2 The Ad5 fiber protein, as well as the majority of the other 48 adenovirus serotypes, utilize CAR in binding to cells. Following attachment, an RGD tripeptide motif in the penton base protein binds to ␣ v integrins which mediate cellular internalization. 3 With the major primary and secondary receptors identified, it has been possible to correlate receptor expression in vivo with the efficiency of transduction by Ad in different tissues. As one might expect, cell types which are difficult to transduce, such as smooth muscle and hematopoietic cells, express little or no CAR. Other tissue types, such as hepatocytes, which are readily transduced by adenovirus express high levels of CAR.
However, the identification of CAR and ␣ v integrins is only part of the story relevant to adenovirus targeting. A number of studies now indicate that the binding of adenovirus to both CAR and ␣ v integrins induces a cascade of intracellular signaling events. 4 These events not only stimulate uptake but may also contribute to some of the immune and inflammatory responses that have been observed in vivo. With regard to fiber, some studies have suggested that MHC may also act as a receptor for adenovirus. 5, 6 With respect to penton base, there is now evidence that it interacts with other integrins in addition to ␣ v , including ␣ 5 ␤ 1 , ␣ m ␤ 2 , and possibly ␣ 6 ␤ 1 . The integrin ␣ m ␤ 2 , which is expressed primarily on macrophages has been shown to mediate direct binding of Ad to cells. This finding is contrary to the standard model when penton base does not directly participate in attachment. In fact, there is now increasing evidence that the ␣ v integrins are able to mediate some virus binding and uptake in the absence of CAR interactions.
In conjunction with research on adenovirus-cell interactions, increased knowledge of particle structure has greatly facilitated efforts to engineer the coat proteins of adenovirus for targeting. For example, cryo-EM studies have revealed the locations of all the coat proteins in the particle, as well as the general location of the RGD motif in the penton base. 7, 8 Even more detail on the protein level has been obtained from the crystal structures of hexon and the fiber knob. 9, 10 These studies have been crucial to coat protein engineering efforts because they have taken the guesswork out of where to insert ligands into the coat proteins. In addition, the structure of the Ad5 knob has been instrumental for our group in delineating the binding site for CAR on the fiber.
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Approaches to targeted adenovirus
There are two things that are necessary to make adenovirus tissue selective: (1) knock out the native receptor interactions and (2) redirect the vector to a new receptor. Generally, this has been accomplished for adenovirus by two separate approaches. The first approach is a twocomponent system in which Ad is complexed with other molecules to redirect binding alone or to both block CAR binding and redirect binding. A second general approach is a one-component system in which the virus particle is genetically modified to ablate native receptor interactions and redirect the virus to a novel receptor.
Two-component targeting
In most instances, two-component targeting has been accomplished through complexing the adenovirus with a bispecific molecule which both blocks the interaction with CAR and redirects the virus to a novel receptor. 12 The bispecific molecule contains a first specificity for the fiber knob and blocks binding to CAR. The second specificity is for a tissue-specific receptor. The CAR-blocking molecule can be a neutralizing antibody, a soluble form of CAR, or a high affinity peptide which binds to the knob. The receptor ligand can be an antibody or fragment of an antibody, a high affinity peptide, or even a small molecule compound which binds to a receptor. The bispecific molecule has been made by covalently attaching the molecules using a variety of linkage chemistries or by expressing a recombinant fusion protein which contains the blocking ligand and the receptor ligand. Other two-component systems for redirecting the virus to a new receptor have included approaches which chemically modify the adenovirus so that ligands can be attached. However, these approaches, thus far, have not tried to ablate the native receptor tropism of adenovirus.
Redirection using a two-component targeting system has been a powerful tool for validating the ability of a particular target receptor to mediate efficient transduction by adenovirus. There is now a growing list of reported target receptors including CD3, E-selectin, ␣ v integrins, the FGF receptor and multiple tumor markers. The biggest advantage of a two-component targeting system is that virtually any receptor can be targeted due to the abundance of readily available high-affinity antibodies that can be used as ligands. Another advantage of the approach is that specialized modifications of coat proteins, as well as special cell lines to grow the adenovirus vector, are not needed.
One-component targeting
One-component targeted vectors are created solely through genetic modification of the adenovirus vector to incorporate targeting ligands and/or ablate the interactions of the fiber and penton base with their native receptors. Initial studies in developing one-component systems focused on the ligand incorporation. By incorporating additional ligands into the coat protein, without ablating native receptor interactions, the tropism of the virus is actually expanded, rather than restricted. For example, 'sticky' vectors, which contain polylysine motifs genetically incorporated into the fiber, have been shown dramatically to enhance the transduction of a variety of cells which lack adenovirus receptors. 13 Further studies using genetically modified, tropism-expanded vectors have shown that they dramatically increase the in vivo transduction of both vascular smooth muscle and certain types of tumors. 14, 15 The development and successful use of these genetically modified vectors with enhanced tropism have been important for two reasons. First, these studies have demonstrated that high-affinity peptide motifs can be functionally incorporated into the adenovirus particle. These motifs can then direct the transduction of cells via a non-native adenovirus receptor. Second, these studies have demonstrated that tropism-modified vectors can be successfully used in vivo.
Issues to consider in incorporating ligands into the coat proteins include the location, the affinity, the size, and the availability of suitable ligands. Although more work will be needed, a great deal has been learned about where ligands can be incorporated. High-affinity peptide ligands have been inserted into the HI loop or on to the C-terminus of fiber, into the RGD loop of penton base, or even into an exposed loop of hexon. It appears that as long as the peptide has a high affinity any of these locations can function in mediating virus attachment and entry. The size and type of ligand that can be inserted into the adenovirus coat proteins is currently a major issue that has not yet been fully addressed. For example, it remains to be determined whether larger protein folding motifs such as single chain antibodies can be successfully incorporated anywhere in the adenovirus.
Certainly, incorporating single chain antibodies into the virus would be a great advantage, but it is not the only solution. It is clear that high-affinity peptide ligands can be incorporated into adenovirus vectors. However, the current major disadvantage of the genetic approach is the availability of high-affinity ligands. Fortunately, this situation appears to be changing with the increased use of peptide display systems to identify high-affinity peptide ligands to an ever-increasing list of important targets. Multiple peptide ligands have been identified which home to particular organs such as the lung, brain, skin, intestines and pancreas, as well as peptides which home to tumors. 16 However, it remains to be seen whether such peptides are functional in directing adenovirus to these targets.
Genetically ablating adenovirus interactions with native receptors has met with two major challenges. The first challenge has been to locate the CAR binding site on fiber. Only recently, the CAR binding domain been identified to allow the generation of mutated fibers lacking CAR binding. 11 A further challenge has been the development of packaging cell lines that support the entry and replication of tissue-specific, CAR-ablated vectors. This has been accomplished by constructing cell lines which express alternate 'pseudoreceptor' targeted adenovirus vectors. 17, 18 These pseudoreceptors act as surrogate receptors which mediate the binding and uptake of targeted vectors in the absence of CAR binding. These pseudoreceptors have been comprised of a receptor transmembrane domain fused to a single-chain antibody which directly recognize one of the coat proteins or recognize a linear peptide epitope genetically incorporated into a coat protein. Using this system, CAR-ablated vectors have been produced which have titers that are equivalent to non-ablated vectors. 11 Furthermore, CARmediated uptake of these vectors has been completely abolished, resulting in 10-to 1000-fold reductions in transduction of CAR-expressing cells. The majority of the residual transduction that occurs in these vectors is integrin dependent. This finding suggests that further ablation can be achieved by mutating the RGD sequence in penton base.
Targeted adenovirus as a drug
In keeping view of the ultimate goal of targeted adenovirus -creating a vector to treat disease -probably the biggest disadvantage of a two-component system is in making it into a product that can be reliably used in clinical trials and then sold commercially. Those companies and institutions now involved in the large-scale production of adenovirus vectors for clinical trials are quickly becoming aware of the enormity of the task to produce and formulate even just first generation vectors successfully. Enormous efforts have been devoted in many companies to produce, purify, quality control, and formulate first-generation adenovirus vectors. With twocomponent systems, there are two components to produce, two components to purify, two components alone and in combination for which quality control assays need to be developed, two components alone and in combination which will likely need to be considered in clinical trials, and finally, two components that need to be rigorously developed into a formulation that can preferably be stored for long periods at a reasonable temperature. For these reasons, the expensive and time-consuming task of developing a two-component system into a gene therapy drug would likely be more difficult compared with a one-component system.
Getting to the target: in vitro to in vivo
Is ablating CAR enough? Because adenovirus utilizes two of its coat proteins to interact with distinct receptors, it is uncertain whether ablating only the CAR interaction is sufficient. According to the standard two-step model for adenovirus in which virus attaches solely through CAR and then is internalized through ␣ v integrins, ablating CAR should be enough. However, as has already been mentioned, Ad5 can attach and enter cells in a CAR-independent manner through penton base. But how significant are CAR-independent routes of entry? There is now emerging evidence suggesting that, in vivo, CAR-independent routes of entry may be significant. For example, direct binding of vector to ␣ m ␤ 2 integrins expressed on Kuppfer cells in the liver could rapidly clear targeted vector from the circulation. In addition, it is unknown how other clearance mechanisms used by the liver will affect targeted gene transfer.
Our in vitro experience with CAR-ablated vectors has shown that transduction of CAR-expressing cells is reduced 10-to 1000-fold compared with a CAR-binding vector. Additional experiments have shown that the majority of the residual transduction is penton base mediated. However, do these 'two-dimensional' experiments, where a liquid layer of virus-containing medium is incubated over a flat layer of cells, really mimic the 'three dimension' situation that occurs in vivo? In the in vitro experiments, the cell concentrations usually do not exceed one million cells per milliliter. In this situation, a given virus may collide with a cell only once per hour. In contrast, the concentration of cells in vivo is about 100-fold higher. The implications of this higher in vivo cell concentration is that the virus is sandwiched between and constantly colliding with cells. In this situation, the previously minor routes of entry via penton base could become very significant.
Challenges to achieving success: generating compelling in vivo proof of principle As mentioned at the outset, the three key potential advantages of targeted adenovirus are in increasing Gene Therapy safety, reducing immune response, and increasing the efficacy and ease of administration of adenovirus vectors. So clearly what is now needed are the in vivo 'proofs of principle' to support each of these potential advantages. If adenovirus particle interactions with cells are contributing to some observed toxicities, then with tropismablated vectors it should be possible to test this hypothesis directly. Likewise, it should now be possible to test whether targeted adenovirus increases persistence or reduces humoral response by avoiding uptake into immune effector cells. Finally, it will not be long before the proof of principle for systemic targeting is realized. What can then be determined is how well it works, what genes can be used, what therapies it can be used for, as well as how it can be used as a tool for other technologies. For example, a tissue-specific vector could be used as a functional genomics tool to screen or select for genes with a desired function in vivo. As these ideas are tested, the unraveling of the key factors controlling tissue tropism will be better understood to allow even better vectors to be made. Ultimately, or in parallel, these advances in 'receptor targeting' of adenovirus can be combined with the 'transcriptional targeting' or adenovirus, as well as improved adenovirus backbones, such as gutless vectors, to create vectors which deliver genes selectively, safely, and with little immune response.
